Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
Fractyl Breaks the Medical Device IPO Drought with New Offering
Medical Devices and Diagnostics Industry
Sun, 02/4/24 - 12:37 pm
Fractyl Health
IPOs
diabetes
obesity
Medtech
FDA approves NeuroBo’s DA-1726 application to begin Phase I trial
Clinical Trials Arena
Fri, 02/2/24 - 11:55 am
NeuroBo Pharmaceuticals
DA-1726
FDA
clinical trials
obesity
Novo Nordisk R&D spend jumps 35% thanks to soaring sales as oral obesity plans advance
Fierce Biotech
Wed, 01/31/24 - 11:55 am
Novo Nordisk
R&D
obesity
amycretin
Will Novo Nordisk Be a $1 Trillion Company by 2030?
Motley Fool
Tue, 01/30/24 - 10:40 am
Novo Nordisk
obesity
diabetes
kidney disease
Fractyl sets out $99M IPO ambitions after busy week of biotechs going public
Fierce Biotech
Mon, 01/29/24 - 11:13 am
IPOs
Fractyl Health
obesity
Lilly's weight-loss drug Mounjaro coming to UK after pen cleared
Reuters
Thu, 01/25/24 - 09:00 pm
Eli Lilly
Mounjaro
UK
obesity
diabetes
Many patients keep weight off after stopping anti-obesity meds: study
Axios
Wed, 01/24/24 - 10:44 am
obesity
Novo Nordisk
Ozempic
Wegovy
Saxenda
Victoza
Scholar Rock gets FDA nod to trial SMA drug with GLP-1ra in obesity
Clinical Trials Arena
Wed, 01/24/24 - 10:38 am
Scholar Rock
clinical trials
apitegromab
obesity
Novo Nordisk Inks Potential $255M Deal with EraCal, Targets Another Obesity Asset
BioSpace
Tue, 01/23/24 - 06:02 pm
Novo Nordisk
obesity
EraCal Therapeutics
United States of Ozempic: Where anti-obesity drugs are taking off
Axios
Fri, 01/19/24 - 09:31 am
Ozempic
Zepbound
Wegovy
Novo Nordisk
Eli Lilly
obesity
United States
JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage
Medical Marketing and Media
Thu, 01/11/24 - 11:18 am
JPMHC 2024
obesity
diabetes
diabesity
Novo Nordisk
Eli Lilly
Amgen has potential to compete with established leaders in obesity drugs
Biopharma Reporter
Thu, 01/11/24 - 11:13 am
Amgen
obesity
JPMHC 2024
JPM24: In booming obesity field, Novo Nordisk is 'just getting going,' CEO says
Fierce Pharma
Wed, 01/10/24 - 06:27 pm
Novo Nordisk
obesity
Wegovy
Lars Fruergaard Jorgensen
JPMHC 2024
Zepbound shortage could be around the corner
Beckers Hospital Review
Tue, 01/9/24 - 10:05 pm
Eli Lilly
Zepbound
obesity
drug shortages
David Ricks
Pharma CEOs
JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach
Fierce Pharma
Tue, 01/9/24 - 10:54 am
Amgen
Pharma CEOs
Bob Bradway
obesity
JPMHC 2024
Zealand raises $212.5M to advance obesity pipeline
Clinical Trials Arena
Tue, 01/9/24 - 09:37 am
Zealand Pharma
obesity
funding
Pfizer to remain aggressive on obesity market after setback
Reuters
Mon, 01/8/24 - 10:19 pm
Pfizer
Albert Bourla
Pharma CEOs
JPMHC 2024
obesity
Rhythm expands obesity portfolio with Phase II weight loss drug for $100m
Clinical Trials Arena
Fri, 01/5/24 - 11:21 am
Rhythm Pharmaceuticals
LG Chem
obesity
LB54640
Lilly launches website, home delivery option for weight-loss drugs
Reuters
Thu, 01/4/24 - 10:07 am
Eli Lilly
obesity
Zepbound
Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals
Fierce Biotech
Thu, 01/4/24 - 10:06 am
Novo Nordisk
Omega Therapeutics
Cellarity
Flagship Pioneering
funding
obesity
NASH
MASH
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »